Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses

Simply Wall St.03-11

Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618991825?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-11 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618991825","market":"us","top_or_hot":-1,"title":"Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses","media":"Simply Wall St.","content":"<div>\n<p>Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/coherus-oncology-chrs-revenue-gains-contrast-with-persistent\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/coherus-oncology-chrs-revenue-gains-contrast-with-persistent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/coherus-oncology-chrs-revenue-gains-contrast-with-persistent\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHRS","symbol_name":"Coherus Biosciences","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/coherus-oncology-chrs-revenue-gains-contrast-with-persistent","article_id":"2618991825","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-chrs/coherus-oncology/news/coherus-oncology-chrs-revenue-gains-contrast-with-persistent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618991825","pubTimestamp":1773192043,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic EPS loss of US$1.56. Over recent quarters, the company has seen revenue move from US$7.6 million in Q1 2025 to US$12.7 million in Q4 2025, with quarterly basic EPS losses in a tight band around US$0.38 to US$0.41. This keeps the focus squarely on how efficiently each extra dollar of sales is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CHRS":"Coherus Biosciences"},"translate_title":"Coherus Oncology(CHRS)收入增长与持续4600万美元的季度亏损形成鲜明对比","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1.5},"content_text":"Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic EPS loss of US$1.56. Over recent quarters, the company has seen revenue move from US$7.6 million in Q1 2025 to US$12.7 million in Q4 2025, with quarterly basic EPS losses in a tight band around US$0.38 to US$0.41. This keeps the focus squarely on how efficiently each extra dollar of sales is being converted as management works on margins. See our full analysis for Coherus Oncology. With the latest results on the table, the next step is to set these figures against the prevailing market narratives around Coherus Oncology and see where the stories align or get challenged. See what the community is saying about Coherus Oncology NasdaqGM:CHRS Earnings & Revenue History as at Mar 2026 AdvertisementLosses Hold Steady Around $46 Million Per Quarter  Across FY 2025, Coherus Oncology booked net losses excluding extra items between about US$44.5 million and US$47.4 million per quarter, even as revenue moved from US$7.6 million in Q1 to US$12.7 million in Q4. Consensus narrative talks about cost discipline and operational efficiency, but these quarterly losses staying tightly clustered around the mid US$40 million range suggest the cost base is still heavy relative to the current US$7.6 million to US$12.7 million revenue run rate.\n     Analysts reference over US$30 million in annualized cost savings after divestitures, yet FY 2025 net income excluding extra items stayed close to the levels seen in late FY 2024 of roughly US$46 million loss per quarter. That pattern leaves the balanced view facing a clear tension, with talk of efficiency on one side and a P&L that still shows similar loss magnitude before extra items on the other.    Forecast 36.5% Revenue Growth Versus Ongoing Losses  Forecasts point to revenue growing about 36.5% per year, while trailing 12 month figures still show a basic EPS loss of US$1.56 and net income excluding extra items of a US$183.1 million loss. Bulls highlight strong growth potential, yet these latest numbers underline that the company is currently unprofitable and is expected to remain unprofitable for at least three years, so the growth story is being weighed against persistent losses.\n     Optimistic views reference long term catalysts around LOQTORZI and the pipeline, but on the reported side FY 2025 quarterly basic EPS stayed in a narrow loss band of roughly US$0.38 to US$0.41. That mix, healthy forecast growth with continuing losses, heavily shapes why bullish investors focus on long dated earnings potential rather than anything visible yet in the recent income statement.    Have a closer look at how those long term growth arguments line up with the current numbers in the detailed bull case for Coherus Oncology, then decide whether the story matches your own expectations. 🐂 Coherus Oncology Bull Case Discounted P/S And DCF Versus Dilution Risk  On valuation markers, Coherus trades on a P/S of 6.9x compared with a 9.2x peer average and 12.3x for the US biotechs industry, and sits well below a stated DCF fair value of about US$29.55 per share with the stock at US$1.95, while shareholders also saw substantial dilution over the past year. Bears point to that dilution and the lack of near term profitability, and the recent figures give them material support even alongside the apparent discount on P/S and DCF fair value.\n     The trailing 12 month net loss excluding extra items of US$183.1 million and the expectation that the company will not reach profitability within three years speak directly to the cautious view on earnings durability. At the same time, the share count increase that created the dilution sits alongside forecasts of continued losses, which is exactly the combination skeptics focus on when they question how quickly any implied valuation gap might realistically close.    If you are weighing that gap between the current price and longer term risk arguments, it is worth reading the detailed bear case for Coherus Oncology so you can see exactly what the cautious side is watching. 🐻 Coherus Oncology Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Coherus Oncology on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With the bull and bear cases laid out, how does it all sit with you right now, and what feels most convincing? Take a moment to scan the figures, weigh both sides, and move quickly to shape your own view by checking the 4 key rewards and 3 important warning signs for this company. Explore Alternatives Coherus Oncology is still posting quarterly losses of roughly US$46 million alongside trailing 12 month net income excluding extra items of a US$183.1 million loss and ongoing EPS losses. If that kind of persistent loss profile makes you want a different balance of risk and reward, take a look at our 68 resilient stocks with low risk scores that focus on companies with more resilient fundamentals right now.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618991825","isCrawlerRequest":true}